Skip to main content
v2026.11,986 entries · CC-BY 4.0
LAC HealthSponsored

Shop scorad supplies

  • FDA registered
  • ISO 13485
  • BBB Accredited A+

Shop at LAC Health

SCORAD: What the Atopic Dermatitis Index Measures

What SCORAD measures, how its items were weighted in 1993, where raters disagree, and how PO-SCORAD and EASI relate.

Written and maintained by CASRAI Editorial Board

Published

On this page

This page explains a research and clinical measurement instrument. It is general information, not medical advice, and it does not tell anyone how to interpret their own or another person’s score.

Short answer

SCORAD (SCORing Atopic Dermatitis) is a clinician-completed index for the severity of atopic dermatitis. It was proposed in 1993 by the European Task Force on Atopic Dermatitis and combines three kinds of information: how much of the body is affected (extent), how severe the skin signs are (intensity), and the patient’s reported symptoms. PO-SCORAD is the patient-completed version derived from it.

Definition and scope

The 1993 consensus report, Severity scoring of atopic dermatitis: the SCORAD index (Dermatology 1993;186(1):23-31, PMID 8435513), describes the index as built from three items: extent, intensity and subjective symptoms. The intensity items studied were erythema, edema/papulation, oozing/crusts, excoriations and lichenification. A 1997 validation paper by Kunz and colleagues (Dermatology 1997;195(1):10-19, PMID 9267730) describes the objective criteria (extent and intensity) and the subjective criteria (daytime pruritus and sleep loss).

SCORAD is a research and clinic assessment tool. It is not a diagnostic test: it presupposes that atopic dermatitis has already been diagnosed and quantifies severity for monitoring and for trial outcomes.

How the index was constructed

This is the part most calculator pages skip. In the 1993 development study, 88 patients at five institutions were scored using two variants of the index, and principal-component analysis was used to decide how much each item should count. The report states that extent and subjective symptoms carry roughly 20% of the weight each, and the intensity items together carry 60%. Two practical choices are documented:

  • Extent by the rule of nine. The authors found the rule of nine for extent more workable than a distribution-times-intensity product.
  • Simplicity over completeness. The final choice was based on simplicity and routine outpatient use, and the report says the index needs to be further tested in clinical trials.

The report also notes that edema/papulation was difficult to assess from slides, which matters for training and photo-based scoring.

How it is used in practice

In the 1997 validation exercise, 23 physicians scored 169 sheets covering 19 patients (14 children and 5 adults) in three scoring sessions in Hamburg, Bordeaux and Rotterdam during 1993 and 1994. Its findings are the most useful evidence for anyone planning to use SCORAD in a study:

  • Inter-observer variability in the rule-of-nine extent estimate was mostly seen in patients with moderate intensity and 20-60% body surface area affected.
  • The intensity items were more consistent between observers, with lower variation for oozing/crusts and lichenification.
  • Training helped.
  • The authors proposed grading severity into three groups by objective criteria for trial inclusion, while SCORAD remained the major criterion for following patients in trials.

The item definitions, calculation and any severity bands are set by the index’s developers, so use the original publication or the developers’ current materials rather than a third-party calculator when a protocol requires a specific method.

Instrument Completed by What the source says
SCORAD Clinician (with patient-reported symptoms) Extent, intensity and subjective symptoms; European Task Force, 1993 (PMID 8435513).
PO-SCORAD Patient Self-assessment derived from SCORAD. A pilot with 15 children and 18 adults found it feasible, with 80% finding the questions clear (PMID 19147989). A later study of 471 patients (185 adults, 286 children) in nine European countries found correlation with SCORAD of r = 0.67 at baseline and r = 0.79 at day 28 (PMID 21414011).
EASI Clinician The instrument agreed by the Harmonising Outcome Measures for Eczema (HOME) initiative for clinician-reported signs; POEM is the agreed patient-reported symptom instrument (HOME VII, Br J Dermatol 2021;185(1):139-146, PMID 33393074).

Where it matters for labs, clinics and trial teams

SCORAD scores appear throughout the atopic dermatitis literature as an outcome and as a severity descriptor; for example, a 2007 study of 117 children reported a mean overall SCORAD of 51.1 and compared biomarker levels across mild, moderate and severe groups (PMID 18173519). For trial design, the practical point is that HOME names EASI and POEM as the preferred instruments for signs and symptoms, so a protocol that uses SCORAD as its primary measure should state why. Rater training and a plan for measuring agreement are justified by the 1997 variability findings; see inter-rater reliability: choosing a coefficient, and choosing and validating a patient-reported outcome measure for the self-report side. For how consensus outcome sets are built, see core outcome sets and the COMET database.

Common misunderstandings

  • SCORAD is not a diagnosis. It scores severity in someone already diagnosed.
  • PO-SCORAD is not identical to SCORAD. It is a separate self-assessment scale. Its correlation with SCORAD is moderate to good (r = 0.67 and 0.79 in the validation study), not perfect.
  • Extent is not the whole score. Intensity items carry most of the weight (about 60%) in the development report.
  • Different scoring systems are not interchangeable. Grading scales such as CTCAE and early-warning scores like the modified early warning score answer different questions; a number from one cannot be converted to another.

FAQ

What does SCORAD stand for?

SCORing Atopic Dermatitis, the index introduced by the European Task Force on Atopic Dermatitis in 1993.

What is PO-SCORAD?

The Patient-Oriented SCORAD, a self-assessment scale derived from SCORAD and validated against it in 471 patients across nine European countries (Allergy 2011;66(8):1114-21).

How does SCORAD relate to EASI?

Both are clinician-completed severity measures. The HOME initiative agreed EASI as its preferred instrument for clinician-reported signs.

Sources

  • Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993;186(1):23-31. PubMed 8435513. Read 2026-11-07.
  • Kunz B et al. Clinical validation and guidelines for the SCORAD index. Dermatology 1997;195(1):10-19. PubMed 9267730. Read 2026-11-07.
  • Vourc’h-Jourdain M et al. Patient-oriented SCORAD: a preliminary feasibility study. Dermatology 2009;218(3):246-51. PubMed 19147989. Read 2026-11-07.
  • Stalder JF et al. PO-SCORAD validated in Europe. Allergy 2011;66(8):1114-21. PubMed 21414011. Read 2026-11-07.
  • Thomas KS et al. HOME VII consensus meeting. Br J Dermatol 2021;185(1):139-146. PubMed 33393074. Read 2026-11-07.
  • Hon KL et al. Age-specific serum IgE and symptomatology in children with atopic dermatitis. Int J Dermatol 2007;46(12):1258-62. PubMed 18173519. Read 2026-11-07.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about SCORAD: What the Atopic Dermatitis Index Measures

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →